Electra Therapeutics highlights ELA026 Phase 1b study in sHLH and presents preclinical data at ASH Annual Meeting
Ongoing Phase 1b study progressing in US and EU for ELA026 in sHLH, a life-threatening inflammatory disease Preclinical data demonstrate ELA026 proof-of-mechanism of SIRP targeting and depletion of pathological immune cells that drive sHLH Company also presents results of sHLH natural history study SOUTH SAN FRANCISCO, CA, December 12, 2022 – Electra Therapeutics, Inc., a clinical […]
Electra Therapeutics to Highlight ELA026 in Three Presentations at the American Society of Hematology (ASH) 2022 Annual Meeting
Company’s lead product candidate, ELA026, is in a clinical study for a life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH) SOUTH SAN FRANCISCO, CA, November 3, 2022 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP), announced today that the company will present three posters related to […]
Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancer
Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) enables specific depletion of pathological immune cells Financing enables lead product candidate, ELA026, to reach clinical proof of concept in the inflammatory disease sHLH, expansion of ELA026 into other indications, and advancement of two additional programs towards the clinic SOUTH SAN FRANCISCO, CA, February 16, […]
